PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25048519-6	2015	Our working hypothesis, to be discussed and partially tested herein, is that CD38, and likely BST1/CD157--both NAD(+) -consuming enzymes, are active in the myeloma niche and lead a discontinuous chain of ectoenzymes whose final products are exploited by the neoplastic plasma cell as part of its local survival strategy.	NAD	111-117	CD38 molecule	Homo sapiens	77-81	
25048519-6	2015	Our working hypothesis, to be discussed and partially tested herein, is that CD38, and likely BST1/CD157--both NAD(+) -consuming enzymes, are active in the myeloma niche and lead a discontinuous chain of ectoenzymes whose final products are exploited by the neoplastic plasma cell as part of its local survival strategy.	NAD	111-117	bone marrow stromal cell antigen 1	Homo sapiens	94-98	
25048519-6	2015	Our working hypothesis, to be discussed and partially tested herein, is that CD38, and likely BST1/CD157--both NAD(+) -consuming enzymes, are active in the myeloma niche and lead a discontinuous chain of ectoenzymes whose final products are exploited by the neoplastic plasma cell as part of its local survival strategy.	NAD	111-117	bone marrow stromal cell antigen 1	Homo sapiens	99-104	
25048519-7	2015	Coadjuvant ectoenzymes include PC-1/CD203a, CD39, and CD73, which control the production of ADO.	Adenosine	92-95	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	44-48	
25048519-7	2015	Coadjuvant ectoenzymes include PC-1/CD203a, CD39, and CD73, which control the production of ADO.	Adenosine	92-95	5'-nucleotidase ecto	Homo sapiens	54-58